BiotechTube

Vyndaqel

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
22
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Transthyretin Familial Amyloid Polyneuropathy

Conditions

Transthyretin Familial Amyloid Polyneuropathy

Trial Timeline

Jan 10, 2014 → Mar 10, 2023

NCT ID
NCT02146378

About Vyndaqel

Vyndaqel is a pre-clinical stage product being developed by Pfizer for Transthyretin Familial Amyloid Polyneuropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT02146378. Target conditions include Transthyretin Familial Amyloid Polyneuropathy.

Hype Score Breakdown

Clinical
5
Activity
2
Company
9
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT02146378Pre-clinicalCompleted

Competing Products

20 competing products in Transthyretin Familial Amyloid Polyneuropathy

See all competitors
ProductCompanyStageHype Score
Eplontersen Solution for InjectionAstraZenecaPhase 1
33
Eplontersen + PlaceboAstraZenecaPhase 3
77
Treatment of transthyretin (ATTR) amyloidosis in observational study settingAstraZenecaPre-clinical
23
EplontersenAstraZenecaPhase 3
77
Eplontersen + PlaceboAstraZenecaPhase 3
77
NNC6019-0001 + Placebo (NNC6019-0001)Novo NordiskPhase 3
76
NNC6019-0001Novo NordiskPhase 2
51
NNC6019-0001 + Placebo (NNC6019-0001)Novo NordiskPhase 2
51
CoramitugNovo NordiskPhase 1
32
TafamidisPfizerPre-clinical
22
TafamidisPfizerPre-clinical
22
tafamidis megluminePfizerApproved
84
Fx-1006APfizerPhase 2
51
TafamidisPfizerPhase 3
76
Tafamidis 61 milligramsPfizerPre-clinical
22
Treatment for TTR amyloidosis + Treatment for TTR amyloidosisPfizerPre-clinical
22
tafamidisPfizerPhase 3
76
TafamidisPfizerApproved
84
TafamidisPfizerPre-clinical
22
Vyndamax (tafamidis 61mg)PfizerPre-clinical
22

Other Products from Pfizer

MeropenemApproved
84
celecoxibApproved
84
13vPnCApproved
84
EtanerceptApproved
84
AtorvastatinApproved
84